Delabeling Antibiotic Allergy in the Solid Organ Transplant Population Using a Multiple Antibiotic Allergy Evaluation Strategy
Transplant Infectious Disease · 2025
DOI: 10.1111/tid.70099 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant Infectious Disease, 2025. Verfasst von Rebecca Lee und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA. Hauptthemen laut MEDLINE: Drug Hypersensitivity, Anti-Bacterial Agents, Organ Transplantation. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, AHRQ HHS, Agency for Healthcare Research and Quality.
Abstract (Originalsprache)
Background
First‐line antibiotics, such as penicillins, cephalosporins, and sulfonamides, are critical for preventing infections in immunocompromised solid organ transplant (SOT) patients. However, many patients are labeled with multiple antibiotic allergies (AALs) prior to transplant, increasing their risk of adverse outcomes. Because these patients often travel long distances and follow complex care plans, minimizing the number of drug allergy clinic (DAC) visits is important to avoid disruption and improve care continuity.
Methods
We conducted a retrospective cohort study of SOT patients evaluated at Vanderbilt University Medical Center outpatient DAC between 2014 and 2024. We assessed the efficacy, feasibility, and efficiency of a multiple antibiotic allergy evaluation strategy (MAAES), where patients with two or more low‐risk AALs underwent consolidated evaluation, testing, and oral challenges, with the goal of delabeling as many as three AALs in a single visit.
Results
Among 184 SOT patients referred for evaluation, the median age was 57 years (IQR 47, 64); 112/184 (61%) were female, and 64/184 (35%) traveled from out‐of‐state. A total of 53 patients (29%) had two or more first‐line AALs. Of these, 49 (93%) had labels successfully removed during their visit: 37 penicillin, 25 cephalosporin, and 24 sulfa allergy labels were delabeled. MAAES reduced the number of required visits to address these AALs by 61%.
Conclusions
MAAES enabled safe, efficient, and consolidated AAL evaluation and removal in SOT patients. In 57% of patients with ≥ 2 first‐line AALs, all were safely delabeled in a single clinic visit, improving care efficiency and antibiotic access. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Department of Pathology, Microbiology, and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
- Institute for Immunology & Infectious Diseases, Murdoch University, Perth, Western Australia, Australia.
ORCID-Profile: Cosby A Stone
Förderung
- NIAID NIH HHS
- AHRQ HHS
- Agency for Healthcare Research and Quality
Zitieren
APA
Lee, R., Koo, G., Krantz, M. S., Allocco, C., Phillips, E. J., & Stone, C. A. (2025). Delabeling Antibiotic Allergy in the Solid Organ Transplant Population Using a Multiple Antibiotic Allergy Evaluation Strategy. Transplant Infectious Disease. https://doi.org/10.1111/tid.70099
Vancouver
Lee R, Koo G, Krantz MS, Allocco C, Phillips EJ, Stone CA. Delabeling Antibiotic Allergy in the Solid Organ Transplant Population Using a Multiple Antibiotic Allergy Evaluation Strategy. Transplant Infectious Disease. 2025. doi:10.1111/tid.70099
BibTeX
@article{Lee2025,
author = {Lee, Rebecca and Koo, Grace and Krantz, Matthew S and Allocco, Christine and Phillips, Elizabeth J and Stone, Cosby A},
title = {Delabeling Antibiotic Allergy in the Solid Organ Transplant Population Using a Multiple Antibiotic Allergy Evaluation Strategy},
journal = {Transplant Infectious Disease},
year = {2025},
doi = {10.1111/tid.70099}
}
EUVIMED